Literature DB >> 7513206

Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

J S Miller1, K A Alley, P McGlave.   

Abstract

We have recently described a marrow stroma-dependent long-term culture system that supports differentiation of CD34+ human marrow primitive progenitors into natural killer (NK) cells. We postulate that CD7 expression may be an early event in commitment of hematopoietic progenitors to the NK lineage. Here we compare the characteristics of CD34+7- and CD34+7+ marrow cells cultivated in the stroma-based NK culture system. These CD34+ populations were further compared with a marrow derived, more committed, CD34-7+ progenitor to emphasize the continuum of NK development and to highlight differences between progenitors in our assays. No progenitor proliferated when plated in media without stroma, underscoring the importance of stroma in NK differentiation. Plating progenitor populations in interleukin-2 containing media directly on preestablished, allogeneic, irradiated marrow stroma for 5 weeks resulted in CD56+CD3- NK cells; however, characteristics of the cultured populations differed. Fold expansion and cloning efficiency of the CD34+7+ population, determined by a functional limiting dilution assay was significantly higher than of the CD34+7- or CD34+7+ populations. This suggests that the CD34+7+ population is highly enriched for an NK progenitor and a possible intermediate in NK lineage differentiation. Further dividing the CD34+7+ population by the relative fluorescence of CD7 into CD34+7+dim and CD34+7+bright populations showed that the CD34+7+bright population exhibited a significantly higher cloning frequency than parallel experiments with CD34+7+dim cells (11.8% +/- 2.4% v 2.4% +/- 0.7%, n = 6; P = .005). Plating of the more primitive CD34+7- population in a transwell system (which separates progenitors from stroma by a microporous membrane) prevents differentiation into NK cells. In contrast, plating of CD34+7+ progenitors in transwells resulted in generation of NK cells. These data suggest that primitive, but not more mature NK progenitors may require direct contact with stroma for the initial differentiation steps. Finally, differentiation of the NK progenitors in this stroma-dependent model results in expression of CD2 not present on any of the starting populations. This observation suggests that marrow stroma can stimulate CD2 expression on NK progenitors in a previously undescribed fashion that may be analogous to the thymic effect on CD2 expression in immature T lymphocytes. These observations identify early steps in the commitment of primitive marrow CD34+ hematopoietic progenitors to a lymphoid lineage and underscore the importance of coexpression of CD7 with CD34 as an early lymphoid commitment characteristic and direct progenitor-stroma interactions in this process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513206

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Authors:  T A Fehniger; E M Bluman; M M Porter; E Mrózek; M A Cooper; J B VanDeusen; S R Frankel; W Stock; M A Caligiuri
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 2.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

3.  Natural killer-cell differentiation by myeloid progenitors.

Authors:  Bartosz Grzywacz; Nandini Kataria; Niketa Kataria; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2010-12-20       Impact factor: 22.113

4.  Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.

Authors:  Robert W Storms; Patrick D Green; Kristine M Safford; Donna Niedzwiecki; Christopher R Cogle; O Michael Colvin; Nelson J Chao; Henry E Rice; Clayton A Smith
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

Review 5.  Stromal-cell regulation of natural killer cell differentiation.

Authors:  Claude Roth; Carla Rothlin; Sylvain Riou; David H Raulet; Greg Lemke
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

6.  Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion.

Authors:  Ana M Frias; Christopher D Porada; Kirsten B Crapnell; Joaquim M S Cabral; Esmail D Zanjani; Graça Almeida-Porada
Journal:  Exp Hematol       Date:  2008-01       Impact factor: 3.084

7.  Leukaemia of natural killer cell large granular lymphocyte type with HLA-DR-CD16-CD56bright+ phenotype.

Authors:  J Prieto; E Ríos; A Parrado; A Martín; J M de Blas; J M Rodríguez
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

8.  CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells.

Authors:  Binqing Fu; Fuyan Wang; Rui Sun; Bin Ling; Zhigang Tian; Haiming Wei
Journal:  Immunology       Date:  2011-04-21       Impact factor: 7.397

9.  The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element.

Authors:  Frank Cichocki; Rebecca J Hanson; Todd Lenvik; Michelle Pitt; Valarie McCullar; Hongchuan Li; Stephen K Anderson; Jeffrey S Miller
Journal:  Blood       Date:  2008-11-05       Impact factor: 22.113

10.  High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.

Authors:  Jan Spanholtz; Marleen Tordoir; Diana Eissens; Frank Preijers; Arnold van der Meer; Irma Joosten; Nicolaas Schaap; Theo M de Witte; Harry Dolstra
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.